-
1.发明申请Hybridization Quantitation Method for Modified Micro-RNA and -DNA Based Oligonucleotides 审中-公开用于修饰的微RNA和基于DNA的寡核苷酸的杂交定量方法公开(公告)号：US20110027798A1
公开(公告)日：2011-02-03
申请号：US12935775
申请日：2009-03-31
申请人： Kenneth K. Chan , Zhongfa Liu , Zhiliang Xie , Guido Marcucci , John C. Byrd , Natarajan Muthusamy , Ramiro Garzon , Shujun Lui
发明人： Kenneth K. Chan , Zhongfa Liu , Zhiliang Xie , Guido Marcucci , John C. Byrd , Natarajan Muthusamy , Ramiro Garzon , Shujun Lui
CPC分类号： C12Q1/6816 , C12Q1/6834 , C12Q2561/125 , C12Q2525/207 , C12Q2521/307 , C12Q2563/131
摘要： Described herein is a method for the qualitative and/or quantitative determination of an analyte in a test sample which includes base pairing at least one oligonucleotide to a capture template having an overhang; and, hybridizing with a detection probe.
摘要翻译： 本文描述了用于定性和/或定量测定测试样品中分析物的方法，该方法包括将至少一种寡核苷酸与具有突出端的捕获模板碱基配对; 并与检测探针杂交。
-
公开(公告)号：US20100256072A1
公开(公告)日：2010-10-07
申请号：US11909559
申请日：2006-03-24
申请人： Danilo Perrotti , Paolo Neviani , Ramasamy Santhanam , John C. Byrd , Guido Marcucci , Natarajan Muthusamy , Ching-Shih Chen
发明人： Danilo Perrotti , Paolo Neviani , Ramasamy Santhanam , John C. Byrd , Guido Marcucci , Natarajan Muthusamy , Ching-Shih Chen
IPC分类号： A61K38/16 , A61K31/4015 , A61K31/352 , G01N33/53 , A61K31/137 , A61P35/02
CPC分类号： A61K31/353 , C12Q1/42 , G01N2500/10
摘要： The invention provides for methods of treating a mammal who has a BCR/ABL-mediated leukemia, including chronic myelogenous leukemia (CML), particularly the blast crisis stage of CML, Philadelphia-positive acute lymphoblastic leukemia (Ph′-ALL), and refractory leukemias. The invention also provides for compounds for the treatment of these leukemias and methods of identifying anti-leukemic agents.
摘要翻译： 本发明提供了治疗具有BCR / ABL介导的白血病的哺乳动物的方法，包括慢性骨髓性白血病（CML），特别是CML的爆发危机阶段，费城阳性急性淋巴细胞白血病（Ph'-ALL）和难治性 白血病。 本发明还提供了用于治疗这些白血病的化合物和鉴定抗白血病药的方法。
-
公开(公告)号：US08633161B2
公开(公告)日：2014-01-21
申请号：US11909559
申请日：2006-03-24
申请人： Danilo Perrotti , Paolo Neviani , Ramasamy Santhanam , John C. Byrd , Guido Marcucci , Natarajan Muthusamy , Ching-Shih Chen
发明人： Danilo Perrotti , Paolo Neviani , Ramasamy Santhanam , John C. Byrd , Guido Marcucci , Natarajan Muthusamy , Ching-Shih Chen
IPC分类号： A61K38/16
CPC分类号： A61K31/353 , C12Q1/42 , G01N2500/10
摘要： The invention provides for methods of treating a mammal who has a BCR/ABL-mediated leukemia, including chronic myelogenous leukemia (CML), particularly the blast crisis stage of CML, Philadelphia-positive acute lymphoblastic leukemia (Ph′-ALL), and refractory leukemias. The invention also provides for compounds for the treatment of these leukemias and methods of identifying anti-leukemic agents.
摘要翻译： 本发明提供了治疗具有BCR / ABL介导的白血病的哺乳动物的方法，包括慢性骨髓性白血病（CML），特别是CML的爆发危机阶段，费城阳性急性淋巴细胞白血病（Ph'-ALL）和难治性 白血病。 本发明还提供了用于治疗这些白血病的化合物和鉴定抗白血病药的方法。
-
公开(公告)号：US08318812B2
公开(公告)日：2012-11-27
申请号：US12302953
申请日：2007-06-01
申请人： John C. Byrd , Danilo Perrotti , Ching-Shih Chen , James T. Dalton , Frank Frissora , Xiaobin Zhao , Qing Liu , Natarajan Muthusamy
发明人： John C. Byrd , Danilo Perrotti , Ching-Shih Chen , James T. Dalton , Frank Frissora , Xiaobin Zhao , Qing Liu , Natarajan Muthusamy
IPC分类号： A61K31/135
CPC分类号： A61K31/137 , A61K45/06
摘要： Methods—for treatment and prevention of lymphoid malignancies, including, but not limited to acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell lymphoma, Acute Myeloid leukemia (AML), and mantle cell lymphoma (MCL). The methods include administration of a therapeutically effective amount of FTY720 (2-Amino-2-[2-(4-octylphenyl)ethyl]propane 1,3-diol hydrochloride) or a derivative, pharmaceutically acceptable salt thereof, or a prodrug thereof to a subject.
摘要翻译： 方法 - 用于治疗和预防淋巴恶性肿瘤，包括但不限于急性淋巴细胞白血病（ALL），慢性淋巴细胞性白血病（CLL），B细胞淋巴瘤，急性骨髓性白血病（AML）和外套细胞淋巴瘤（MCL）。 所述方法包括将治疗有效量的FTY720（2-氨基-2- [2-（4-辛基苯基）乙基]丙烷-1,3-二醇盐酸盐）或其衍生物，药学上可接受的盐或其前药给予 课程。
-
5.发明申请Methods and Compositions for Delivering Therapeutic Agents in the Treatment of B-Cell Related Disorders 审中-公开在治疗B细胞相关疾病中提供治疗药物的方法和组合物公开(公告)号：US20110280913A1
公开(公告)日：2011-11-17
申请号：US13056009
申请日：2009-07-28
申请人： John C. Byrd , Natarajan Muthusamy , Robert J. Lee , James L. Lee , Rosa Lapalombella , Bo Yu
发明人： John C. Byrd , Natarajan Muthusamy , Robert J. Lee , James L. Lee , Rosa Lapalombella , Bo Yu
IPC分类号： A61K9/00 , C12N5/0781 , A61P37/04 , G01N33/566 , A61K35/02 , A61K39/395 , C12Q1/02
CPC分类号： A61K9/0019 , A61K31/454 , A61K39/39558 , A61K2300/00
摘要： Methods and compositions for treating and/or diagnosing a B-cell malignancy are described.
摘要翻译： 描述了用于治疗和/或诊断B细胞恶性肿瘤的方法和组合物。
-
公开(公告)号：US08309768B2
公开(公告)日：2012-11-13
申请号：US13305927
申请日：2011-11-29
IPC分类号： C07C215/00 , C07C211/00 , C07C213/00
CPC分类号： C07C217/74 , C07C217/64 , C07C2601/02
摘要： A number of FTY720-derived compounds with antitumor activity are described. These compounds include the compounds of formula I: wherein R1 is independently selected from the group consisting of hydrogen, methyl. methoxy, and hydroxyl; R2 is independently selected from the group consisting of hydrogen, methoxy, and hydroxyl; R3 is independently selected from the group consisting of alkyl and cyclo-alkyl; and n is independently selected from 0 to 6. The compounds have lower immunosuppressive side effects as a result of not being phosphorylated by sphingosine kinase 2.
摘要翻译： 描述了许多具有抗肿瘤活性的衍生自FTY720的化合物。 这些化合物包括式I化合物：其中R 1独立地选自氢，甲基。 甲氧基和羟基; R2独立地选自氢，甲氧基和羟基; R3独立地选自烷基和环烷基; 并且n独立地选自0至6.由于不被鞘氨醇激酶2磷酸化，所述化合物具有较低的免疫抑制副作用。
-
公开(公告)号：US20120136063A1
公开(公告)日：2012-05-31
申请号：US13305927
申请日：2011-11-29
IPC分类号： A61K31/137 , A61P35/00 , C07C215/28
CPC分类号： C07C217/74 , C07C217/64 , C07C2601/02
摘要： A number of FTY720-derived compounds with antitumor activity are described. These compounds include the compounds of formula I: wherein R1 is independently selected from the group consisting of hydrogen, methyl. methoxy, and hydroxyl; R2 is independently selected from the group consisting of hydrogen, methoxy, and hydroxyl; R3 is independently selected from the group consisting of alkyl and cyclo-alkyl; and n is independently selected from 0 to 6. The compounds have lower immunosuppressive side effects as a result of not being phosphorylated by sphingosine kinase 2.
摘要翻译： 描述了许多具有抗肿瘤活性的衍生自FTY720的化合物。 这些化合物包括式I化合物：其中R 1独立地选自氢，甲基。 甲氧基和羟基; R2独立地选自氢，甲氧基和羟基; R3独立地选自烷基和环烷基; 并且n独立地选自0至6.由于不被鞘氨醇激酶2磷酸化，所述化合物具有较低的免疫抑制副作用。
-
公开(公告)号：US20100022655A1
公开(公告)日：2010-01-28
申请号：US12302953
申请日：2007-06-01
申请人： John C. Byrd , Danilo Perrotti , Ching-Shih Chen , James T. Dalton , Frank Frissora , Xiaobin Zhao , Qing Liu , Natarajan Muthusamy
发明人： John C. Byrd , Danilo Perrotti , Ching-Shih Chen , James T. Dalton , Frank Frissora , Xiaobin Zhao , Qing Liu , Natarajan Muthusamy
IPC分类号： A61K31/137 , A61P35/02
CPC分类号： A61K31/137 , A61K45/06
摘要： Methods—for treatment and prevention of lymphoid malignancies, including, but not limited to acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell lymphoma, Acute Myeloid leukemia (AML), and mantle cell lymphoma (MCL). The methods include administration of a therapeutically effective amount of FTY720 (2-Amino-2-[2-(4-octylphenyl)ethyl]propane 1,3-diol hydrochloride) or a derivative, pharmaceutically acceptable salt thereof, or a prodrug thereof to a subject.
摘要翻译： 方法 - 用于治疗和预防淋巴恶性肿瘤，包括但不限于急性淋巴细胞性白血病（ALL），慢性淋巴细胞性白血病（CLL），B细胞淋巴瘤，急性骨髓性白血病（AML）和外套细胞淋巴瘤（MCL）。 所述方法包括将治疗有效量的FTY720（2-氨基-2- [2-（4-辛基苯基）乙基]丙烷-1,3-二醇盐酸盐）或其衍生物，药学上可接受的盐或其前药给予 课程。
-
9.发明申请FTY720 Increases CD74 Expression and Sensitizes Cancer Cells to Anti-CD74 Antibody-Mediated Cell Death 有权FTY720增加CD74表达并将癌细胞增殖为抗CD74抗体介导的细胞死亡公开(公告)号：US20130022541A1
公开(公告)日：2013-01-24
申请号：US13551866
申请日：2012-07-18
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2833 , C07K2317/24 , C07K2317/73 , A61K2300/00
摘要： Disclosed herein are methods and compositions comprising fingolimod and anti-CD74 antibodies or fragments thereof. In preferred embodiments, the fingolimod increases the expression of CD74 in target cells and increases the sensitivity of the cells to the cytotoxic effects of the anti-CD74 antibodies. The compositions and methods are of use to treat diseases involving CD74+ cells, such as cancer cells, autoimmune disease cells or immune dysfunction disease cells.
摘要翻译： 本文公开了包含芬戈莫德和抗CD74抗体或其片段的方法和组合物。 在优选的实施方案中，芬戈莫德增加靶细胞中CD74的表达，并增加细胞对抗CD74抗体的细胞毒性作用的敏感性。 组合物和方法可用于治疗涉及CD74 +细胞的疾病，例如癌细胞，自身免疫疾病细胞或免疫功能障碍疾病细胞。
-
公开(公告)号：US20180140602A1
公开(公告)日：2018-05-24
申请号：US15564463
申请日：2016-04-07
申请人： Daniela Angst , John Byrd , Jason Dubovsky , Joseph A. Fraietta , Francois Gessier , Saar Gill , Amy Johnson , Carl H. June , Marcela Maus , Natarajan Muthusamy , David L. Porter , Marco Ruella , Anna Vulpetti , Mariusz Wasik , Novartis AG , The Trustees of the University of Pennsylvania
发明人： Daniela Angst , John Byrd , Jason Dubovsky , Joseph A. Fraietta , Francois Gessier , Saar Gill , Amy Johnson , Carl H. June , Marcela Maus , Natarajan Muthusamy , David L. Porter , Marco Ruella , Anna Vulpetti , Mariusz Wasik
IPC分类号： A61K31/505 , A61K35/17 , C07K16/28 , A61K31/506 , C07K16/30 , A61P35/00 , A61P35/02
CPC分类号： A61K31/505 , A61K31/506 , A61K35/17 , A61K45/06 , A61K2035/124 , A61K2039/505 , A61K2039/545 , A61P35/00 , A61P35/02 , C07K16/2803 , C07K16/30 , C07K2317/24 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C12N5/0636 , A61K2300/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a BTK inhibitor, e.g., an amino pyrimidine derivative described herein. The invention also provides kits and compositions described herein.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.036 秒)
